Thu, Mar 5, 2015, 10:10 AM EST - U.S. Markets close in 5 hrs 50 mins


% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • mining_phd mining_phd Oct 26, 2012 11:26 AM Flag

    Why I favor CYCC over SNSS


    It is my view that SNSS's Voreloxin will have great difficulty competing with CYCC. First of all, their study is being combined w/ Cytarabine for refractory AML. This is a flawed strategy. Refractory patients will be too frail for this type of regimen and will never initiate such treatment. SAPA/DAC will ultimately be approved for front line AML and due to the lower toxicity of this regimen, no better long term maintenance drug combination other than SAPA/DAC will be available. The hint of this is the huge reduction in the 60 day mortality rate in the SAPA/DAC pilot arm study. I believe this hypothesis will be confirmed by the mature data of the Seamless pilot arm which will available by the end of this year. As a side note, Voreloxin has a rather nasty side effect of muccocystic oral lesions and is IV administered.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.266+0.106(+4.91%)10:09 AMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.